Clinical trials: Liver Fibrosis
Liver Fibrosis, Cirrhosis
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
This prospective and multicenter study is to determine the diagnostic performance (accuracy, specificity and sensitivity) of transient elastography (FibroTouch) for liver fibrosis assessment in chronic hepatitis B (CHB) patients…
- Conditions
- Liver Fibrosis, Cirrhosis, Chronic Hepatitis B
- Trial name
- NCT02476695
- Testing
- FibroTouch Examination, FibroScan Examination, Ultrasonic B Examination
- Where
- 15 sites in China
- Volunteers
- 412 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Chronic Hepatitis C Virus, Hepatitis C, Chronic
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
- Conditions
- Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis
- Trial name
- NCT05904470
- Testing
- Bemnifosbuvir, Ruzasvir
- Where
- 51 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide
The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B.
- Trial name
- NCT07295873
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate（TDF）, Tenofovir alafenamide（TAF）
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hypoalbuminemia, Hepatic Cirrhosis
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA.
- Trial name
- NCT06355479
- Testing
- OsrHSA, Plasbumin®-20
- Where
- 37 sites in China
- Volunteers
- 328 people
- Sponsor
- Healthgen Biotechnology Corp.
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Primary Biliary Cholangitis
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA).
- Trial name
- IDEAL (NCT06060665)
- Testing
- Seladelpar 10 mg
- Where
- 45 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- Gilead Sciences
Metabolic Dysfunction-associated Steatohepatitis
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
- Trial name
- NEBULA-1 (NCT07701993)
- Testing
- Efimosfermin alfa
- Where
- 15 sites in United States, Japan
- Volunteers
- 1,740 people
- Sponsor
- GlaxoSmithKline
Hepatic Cirrhosis
Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis
This is an open, randomized study in patients with different severity stages of hepatic cirrhosis, in which rater pairs will be used for the assessment of the intra- and inter-rater reproducibility of NRL972 pharmacokinetics and…
- Trial name
- NCT00896597
- Testing
- NRL972
- Where
- Romania
- Volunteers
- 240 people
- Sponsor
- Norgine
Liver Cirrhosis
Alfapump-albumin Replacement Therapy
The study will be a single centre, open-label trial. The patients will have a diagnosis of refractory ascites and will meet specified inclusion/exclusion criteria Informed consent will be obtained from all patients.
- Trial name
- NCT02448160
- Testing
- alfapump, salt-poor Human Albumin solution
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Sequana Medical N.V.
Liver Cirrhosis
Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis
Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis.
- Trial name
- LC (NCT01573923)
- Testing
- mesenchymal stem cells, Conventional therapy
- Where
- 6 sites in China
- Volunteers
- 320 people
- Sponsor
- Alliancells Bioscience Corporation Limited
Chronic Liver Disease
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis
This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.
- Trial name
- MBT (NCT00736840)
- Testing
- c13 methacetin solution with breath analyzer
- Where
- 11 sites in United States, Israel
- Volunteers
- 414 people
- Sponsor
- Meridian Bioscience, Inc.
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Liver Transplant, Hepatitis C
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver.
- Trial name
- NCT00260208
- Testing
- Cyclosporine A, Tacrolimus
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 361 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B With Hepatic Fibrosis
A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver…
- Trial name
- NCT07364448
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Alcoholic Cirrhosis
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
The goal of this clinical trial is to evaluate the efficacy and safety of Cellgram-LC in patients with alcoholic cirrhosis. The main questions it aims to answer are: Is Cellgram-LC superior to best supportive care (BSC) in…
- Trial name
- Cellgram-LC (NCT04689152)
- Testing
- Cellgram-LC, Best Supportive Care (BSC)
- Where
- 15 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Pharmicell Co., Ltd.
Ascites, Hepatic Cirrhosis
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.
- Trial name
- NCT01349348
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 535 people
- Sponsor
- Otsuka Beijing Research Institute
Cholestasis
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC).
- Trial name
- NCT02966834
- Testing
- GSK2330672
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Primary Biliary Cirrhosis
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or…
- Trial name
- NCT02955602
- Testing
- MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Gilead Sciences
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens
Liver Cirrhosis, Biliary
Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)
- Trial name
- NCT00406237
- Testing
- tigecycline
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer